IMVAMUNE: Modified Vaccinia Ankara Strain As an Attenuated Smallpox Vaccine

Overview

Journal Expert Rev Vaccines

Date 2008 Dec 20

PMID 19093767

Citations 69

Authors

Jeffrey S Kennedy

Richard N Greenberg

Affiliations

Soon will be listed here.

Abstract

Smallpox vaccines based on replicating vaccinia virus are known to elicit rare yet serious adverse events, particularly in human populations with immune deficiency, atopic dermatitis and at the extremes of age. A vaccine that induces protective immune responses equivalent to first-generation smallpox vaccines while reducing the risk for severe adverse events is critical for a national stockpile of smallpox vaccines. Modified vaccinia Ankara (MVA) has been proposed as an immediate solution for vaccination of high-risk individuals. Bavarian Nordic's vaccine MVA-BN (IMVAMUNE) is a MVA strain that is replication incompetent in mammalian cell lines. IMVAMUNE has been administered to more than 1900 human subjects to date, including high-risk populations (e.g., people diagnosed with atopic dermatitis or infected with HIV) in which standard replicating vaccines are contraindicated. We review the Phase I clinical trial safety profile and immune responses and compare them with other smallpox vaccines, including ACAM2000 and Dryvax.

Citing Articles

Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models.

Tscherne A, Meyer Zu Natrup C, Kalodimou G, Volz A Methods Mol Biol. 2024; 2860:297-340.

PMID: 39621276 DOI: 10.1007/978-1-0716-4160-6_20.

Advancements in monkeypox vaccines development: a critical review of emerging technologies.

Garcia-Atutxa I, Mondragon-Teran P, Huerta-Saquero A, Villanueva-Flores F Front Immunol. 2024; 15:1456060.

PMID: 39464881 PMC: 11502315. DOI: 10.3389/fimmu.2024.1456060.

Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.

Hsu J, Kim S, Anandasabapathy N Viruses. 2024; 16(6).

PMID: 38932162 PMC: 11209207. DOI: 10.3390/v16060870.

Third-generation smallpox vaccines induce low-level cross-protecting neutralizing antibodies against Monkeypox virus in laboratory workers.

Jandrasits D, Zust R, Siegrist D, Engler O, Weber B, Schmidt K Heliyon. 2024; 10(10):e31490.

PMID: 38826712 PMC: 11141380. DOI: 10.1016/j.heliyon.2024.e31490.

A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models.

Su C, Li S, Wen Y, Geng X, Yin Q, Wang Y Vaccines (Basel). 2024; 12(4).

PMID: 38675767 PMC: 11053415. DOI: 10.3390/vaccines12040385.

References

Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H . Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest. 2008; 118(5):1776-84. PMC: 2289795. DOI: 10.1172/JCI33940. View

Poland G, Grabenstein J, Neff J . The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine. 2005; 23(17-18):2078-81. DOI: 10.1016/j.vaccine.2005.01.012. View

Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, Sutter G . Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol. 2007; 81(22):12102-10. PMC: 2168990. DOI: 10.1128/JVI.01190-07. View

Greenberg R, Kennedy J . ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs. 2008; 17(4):555-64. PMC: 9491136. DOI: 10.1517/13543784.17.4.555. View

Meyer H, Sutter G, Mayr A . Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol. 1991; 72 ( Pt 5):1031-8. DOI: 10.1099/0022-1317-72-5-1031. View

Hochstein-Mintzel V, Hanichen T, Huber H, STICKL H . [An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)]. Zentralbl Bakteriol Orig A. 1975; 230(3):283-97. View

Meltzer M . Risks and benefits of preexposure and postexposure smallpox vaccination. Emerg Infect Dis. 2004; 9(11):1363-70. PMC: 3035543. DOI: 10.3201/eid0911.030369. View

Ferrier-Rembert A, Drillien R, Tournier J, Garin D, Crance J . Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine. 2008; 26(14):1794-804. DOI: 10.1016/j.vaccine.2007.12.059. View

Carroll M, Moss B . Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997; 238(2):198-211. DOI: 10.1006/viro.1997.8845. View

10.

Hata T, Gallo R . Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008; 27(2):144-50. PMC: 2546601. DOI: 10.1016/j.sder.2008.04.002. View

11.

Henderson D . Smallpox: clinical and epidemiologic features. Emerg Infect Dis. 1999; 5(4):537-9. PMC: 2627742. DOI: 10.3201/eid0504.990415. View

12.

Vollmar J, Arndtz N, Eckl K, Thomsen T, Petzold B, Mateo L . Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2005; 24(12):2065-70. DOI: 10.1016/j.vaccine.2005.11.022. View

13.

Greenberg R, Kennedy J, Clanton D, Plummer E, Hague L, Cruz J . Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet. 2005; 365(9457):398-409. DOI: 10.1016/S0140-6736(05)17827-1. View

14.

Earl P, Americo J, Wyatt L, Espenshade O, Bassler J, Gong K . Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A. 2008; 105(31):10889-94. PMC: 2495015. DOI: 10.1073/pnas.0804985105. View

15.

Marennikova S, Maltseva N . [COMPARATIVE STUDY OF SOME STRAINS OF VACCINIA VIRUS. II. PATHOGENICITY FOR LABORATORY ANIMALS]. Vopr Virusol. 1964; 126:287-91. View

16.

Fulginiti V, Papier A, Lane J, Neff J, Henderson D . Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis. 2003; 37(2):251-71. DOI: 10.1086/375825. View

17.

MUNZ E, Linckh S, Reimann M . [The effectiveness of immunization with vaccinia virus type "MVA" against an infection with cowpox virus type "OPV 85" in rabbits]. Zentralbl Veterinarmed B. 1993; 40(2):131-40. View

18.

Arness M, Eckart R, Love S, Atwood J, Wells T, Engler R . Myopericarditis following smallpox vaccination. Am J Epidemiol. 2004; 160(7):642-51. DOI: 10.1093/aje/kwh269. View

19.

Mayr A . [Development of of non-immunising, paraspecific vaccine from attenuated pox viruses: a new type of vaccine]. Berl Munch Tierarztl Wochenschr. 2001; 114(5-6):184-7. View

20.

Galasso G, MATTHEIS M, Cherry J, Connor J, McIntosh K, BENENSON A . Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary. J Infect Dis. 1977; 135(1):183-6. DOI: 10.1093/infdis/135.1.183. View